ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit

TORONTO and CAMBRIDGE, MA, Sept. 16, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced that Executive Chairman, Eugene Williams will participate on an executive panel at the Fall Investor Summit being held today at noon at the JW Marriot Essex House, 160 Central Park South, New York, NY.  

ProMIS Neurosciences Inc. (CNW Group/ProMIS Neurosciences Inc.)

Mr. Williams will underline the importance of using novel blood-based biomarkers to significantly shorten drug development timelines and reduce costs for developing disease-modifying therapies specifically in neurodegenerative disease such as Alzheimer's disease, Parkinson's disease and ALS (amyotrophic lateral sclerosis).  

Participants include:

  • Moderator: John Vandermosten, Senior Biotech Analyst at Zacks Investment Research
  • Gene Williams, Executive Chairman, ProMIS Neurosciences
  • James Shanahan, Co-founder & VP of Business Development, SynDevRx
  • Jeff Galvin, CEO, American Gene Technologies
  • Scott Powell, CFO, VolitionRx
  • Alan Joslyn, CEO, Oragenics

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

To learn more, visit us at, follow us on Twitter and LinkedIn and listen to the podcast, Saving Minds, at iTunes or Spotify.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Cision View original content to download multimedia:

SOURCE ProMIS Neurosciences Inc.